Method of enhancing an antitumor T cell response by administering an anti-IL-6 receptor antibody
US9539322B2 · kind B2 · utility
12Cited by
25References
2Claims
0Family size
Assignees
Inventor
Key dates
| Filing date | May 27, 2011 |
| Grant date | Jan 10, 2017 |
| Priority date | — |
| Expiry date | May 27, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K16/2866
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
An objective of the present invention is to provide novel therapeutic agents for cancer, which have an excellent antitumor effect in cancer patients by enhancing their immune function. The present inventors discovered that the administration of at IL-6 inhibitor and/or gemcitabine or a salt thereof to tumor-bearing organisms yields an excellent antitumor T cell response-enhancing effect, and completed the present invention. In addition, the present inventors discovered that the T cell response-enhancing effect produces an excellent antitumor effect.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.